Scorpius Expands Biomanufacturing Services with New U.S. Biotech Partnership

• Scorpius Holdings enters partnership with U.S.-based biotech for research cell bank transfer.

• Partnership to support biomanufacturing activities at Scorpius’ San Antonio facility.

Scorpius Holdings, Inc., an integrated contract development and manufacturing organization (CDMO) has announced a strategic partnership with a U.S.-based biotech company to expand its biomanufacturing capabilities. As part of this agreement, the biotech firm will transfer a research cell bank (RCB) to Scorpius’ facilities in San Antonio, Texas, where biomanufacturing activities will take place.

The partnership highlights Scorpius’ role in providing comprehensive support to biotech firms. According to Jeff Wolf, CEO of Scorpius, the company is seeing an increasing demand from U.S.-based biotech companies for biomanufacturing support. Scorpius offers services that cover early-stage development, preclinical manufacturing, and cGMP clinical manufacturing, supporting both mammalian and microbial programs.

“This partnership underscores Scorpius’ ability to support biotech companies at every stage of their journey, from innovative research to clinical trials,” Wolf said. He also emphasised the company’s focus on flexibility and responsiveness, distinguishing it from larger CDMOs.